

Special Issue

Novel Preventive and Therapeutic Strategies to Eradicate Biofilm Infections Based on New Antibacterial Compounds

Message from the Guest Editor

Biofilm-related infections pose a significant challenge in modern medicine, contributing to persistent and treatment-resistant infections. This Special Issue focuses on novel antibacterial compounds and alternative approaches to combat biofilm infections, aiming to reduce reliance on traditional antibiotics. We welcome the submission of original research papers, short communications, reviews, case reports, and perspectives on, but not limited to, the following topics:

- Novel antibacterial agents targeting biofilms;
- Combination therapies for enhanced biofilm eradication;
- Anti-biofilm peptides and enzymes;
- Bacteriophage-based strategies;
- Immunotherapeutic and host-directed approaches;
- Biomaterial innovations to prevent biofilm formation;
- Natural and synthetic inhibitors of biofilm development;
- Gut microbiota modulation for biofilm control.

Submitted manuscripts should emphasize strategies for overcoming biofilm-related infections while minimizing antibiotic dependence.

Guest Editor

Dr. María Guembe

Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain

Deadline for manuscript submissions

31 October 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/234423

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)